Last reviewed · How we verify
NCT03619564: CKDOD
Chronic Kidney Disease Observational Database - Taiwan
trial in Chronic Kidney Insufficiency in 1,000 participants. Completed in 28 September 2021.
28 September 2021
Quick facts
| Lead sponsor | Fresenius Kabi |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 1 August 2018 |
| Primary completion | 28 September 2021 |
| Estimated completion | 28 September 2021 |
| Sites | 9 locations across Taiwan |
Conditions studied
- Chronic Kidney Insufficiency — all drugs for Chronic Kidney Insufficiency →
Sponsor
Fresenius Kabi — full company profile →
Who can join
20 and older, any sex, with Chronic Kidney Insufficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine the effect of a ketoanalogue supplemented very low protein diet on eGFR decline in chronic kidney disease compared to a low protein diet (0.6 g/kg, LPD) or no protein restriction.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03619564
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Kidney Insufficiency
Currently open trials in the same condition.
- NCT06886256 — Prehabilitation for Kidney Transplant Candidates · NA · recruiting
- NCT06238310 — Comparison of Two Different External Clearance Markers - Mannitol and Iohexol for Measuring Glomerular Filtration Rate · NA · recruiting
- NCT04334707 — Kidney Precision Medicine Project · recruiting
- NCT03991169 — Oral Iron in Children With Chronic Kidney Disease · Phase 4 · recruiting
Other Fresenius Kabi trials
Trials by the same sponsor.
- NCT06274788 — Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Ome · recruiting
- NCT05190484 — bIosimilar of aDalimumab, an European evAluation · unknown
- NCT04807478 — Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC) · withdrawn
- NCT05257031 — Efficacy and Safety of SmofKabiven Extra Nitrogen for Parenteral Nutrition in Patients Receiving Intensive Care · Phase 3 · completed
- NCT05051943 — A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Respon · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03619564 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fresenius Kabi
- Last refreshed: 22 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03619564.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing